WeTrials

A Two-part Phase I, Open Label, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Pyrotinib in Patients With HER2-positive Solid Tumors Whose Disease Progressed on Prior HER2 Targeted Therapy

What is this study?

This study is testing a medication called pyrotinib for people with advanced cancers that have a specific marker called HER2. Researchers want to find the safest and most effective dose of this drug for patients whose previous treatments have stopped working.

Who can participate?

You might be able to join if you are 18 or older, can still do your normal daily activities, and have a confirmed HER2-positive cancer. However, you cannot join if you have trouble swallowing pills or have received recent cancer treatments within the last few weeks.

What will happen?

You will take the study medication as a pill while doctors carefully monitor your health and safety. The study helps researchers figure out the best dose and see how well the treatment shrinks tumors.

Where and when?

The study takes place at locations in Orange and Sacramento, California, as well as Sarasota, Florida. The current status of the study is not fully updated, so you will need to check with the study team for the latest details.

Key Points
  • 1Tests the targeted cancer drug pyrotinib for HER2-positive tumors
  • 2Open to adults 18 and older who can swallow pills and meet health requirements
  • 3Takes place at medical centers in California and Florida

No related links yet

Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Breast CancerGastric CancerSolid TumorsNSCLC

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.